Curemeta
CureMeta is a Boston-based biotech company focused on developing antibodies and antibody-drug conjugates (ADCs) to treat and cure metastatic cancers. Their strategy involves targeting embryonic cancer markers that are not present in normal tissues, aiming to address the unmet needs in metastatic cancer treatment. They have developed proprietary platforms for antibody discovery and have a pipeline of novel therapeutics, including lead candidates CM-09 and CM-14, which target the cancer stem cell marker TRA-1-60. CureMeta is transitioning from preclinical to clinical trials, with plans to initiate human studies for their promising therapies.
Industries
Nr. of Employees
small (1-50)
Curemeta
Patents
Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
US-10509038-B2
View Details
Podocalyxin and TRA-related antibody, methods of preparation and uses as an anti-cancer therapeutic agent
US-10509038-B2
View DetailsProducts
Lead antibody-drug conjugate targeting embryonic-stage glycan (TRA-1-60) with MMAE payload
Preclinical antibody-drug conjugate comprising a monoclonal IgG1 antibody specific for an embryonic-stage glycan target expressed on aggressive tumor cells, conjugated via a cleavable valine-citrulline peptide linker to an MMAE cytotoxic payload. Demonstrated target-dependent internalization and antitumor activity in cell-based assays, xenograft, and PDX mouse models; a humanized antibody version is advanced for clinical development.
CM-09
CM-09 is an antibody-drug-conjugate cancer drug consisting of Bstrongximab, a human/mouse chimeric IgG1 antibody with high specificity and affinity to TRA-1-60, linked to the toxin Mono-Methyl Auristatin E. It is internalized into cancer cells where the toxin is released causing cell death, providing a highly specific targeted mechanism of action for difficult-to-treat cancers.
CM-14
A humanized IgG1 monoclonal antibody with high affinity and specificity to the cancer stem cell marker TRA-1-60, designed as a first-in-class humanized ADC for treating pancreatic and gastric cancers.
Bstrongximab
A therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.
TRA-1-60
TRA-1-60 is a large carbohydrate molecule highly present on normal human embryonic stem cells during embryogenesis and is present on the cell surface of cancer cells in aggressive and metastatic tumors. It serves as an important tumor marker in many kinds of cancer, including metastatic gastric cancer.
Bstrazumab
A humanized IgG1 therapeutic antibody developed by CureMeta targeting cancer.
Lead antibody-drug conjugate targeting embryonic-stage glycan (TRA-1-60) with MMAE payload
Preclinical antibody-drug conjugate comprising a monoclonal IgG1 antibody specific for an embryonic-stage glycan target expressed on aggressive tumor cells, conjugated via a cleavable valine-citrulline peptide linker to an MMAE cytotoxic payload. Demonstrated target-dependent internalization and antitumor activity in cell-based assays, xenograft, and PDX mouse models; a humanized antibody version is advanced for clinical development.
CM-09
CM-09 is an antibody-drug-conjugate cancer drug consisting of Bstrongximab, a human/mouse chimeric IgG1 antibody with high specificity and affinity to TRA-1-60, linked to the toxin Mono-Methyl Auristatin E. It is internalized into cancer cells where the toxin is released causing cell death, providing a highly specific targeted mechanism of action for difficult-to-treat cancers.
CM-14
A humanized IgG1 monoclonal antibody with high affinity and specificity to the cancer stem cell marker TRA-1-60, designed as a first-in-class humanized ADC for treating pancreatic and gastric cancers.
Bstrongximab
A therapeutic monoclonal antibody specific to the cancer target TRA-1-60, an embryonic target present in many cancers including gastric, prostate, and pancreatic cancer cells.
TRA-1-60
TRA-1-60 is a large carbohydrate molecule highly present on normal human embryonic stem cells during embryogenesis and is present on the cell surface of cancer cells in aggressive and metastatic tumors. It serves as an important tumor marker in many kinds of cancer, including metastatic gastric cancer.
Bstrazumab
A humanized IgG1 therapeutic antibody developed by CureMeta targeting cancer.
Services
Design and preclinical development of antibody-drug conjugates including antibody selection, linker/payload pairing, conjugation, and in vitro/in vivo efficacy testing.
Immunohistochemical staining and prevalence analysis for cancer-specific targets in tumor specimens to support target selection and translational development.
Program planning for IND-enabling studies and activities required to prepare and submit an IND and initiate Phase I clinical trials.
Engagement with external investors and development partners to advance preclinical assets toward clinical development.
Design and preclinical development of antibody-drug conjugates including antibody selection, linker/payload pairing, conjugation, and in vitro/in vivo efficacy testing.
Immunohistochemical staining and prevalence analysis for cancer-specific targets in tumor specimens to support target selection and translational development.
Program planning for IND-enabling studies and activities required to prepare and submit an IND and initiate Phase I clinical trials.
Engagement with external investors and development partners to advance preclinical assets toward clinical development.
Expertise Areas
- Antibody discovery and development
- Antibody-drug conjugate (ADC) development
- Preclinical efficacy testing (xenograft and PDX)
- Biomarker identification and validation
Key Technologies
- Monoclonal antibody generation
- Antibody humanization
- Antibody-drug conjugation
- Cleavable peptide linker (valine-citrulline)
News & Updates
Upcoming Events
Begin IND-enabling studies in January 2025, file IND with FDA, and start Phase 1 clinical study with pancreatic and gastric cancer patients by July 2026.
A study on the significance of TRA-1-60 on aggressive gastric adenocarcinoma showing therapeutic impact of CureMeta’s antibody-drug-conjugate CM-09 in a metastatic gastric cancer mouse model.
Patent on TRA-1-60 antibody
Filed patents on 11 antibodies specific to human cancers, including the lead therapeutic antibody Bstrongximab targeting TRA-1-60.
Upcoming Events
Begin IND-enabling studies in January 2025, file IND with FDA, and start Phase 1 clinical study with pancreatic and gastric cancer patients by July 2026.
A study on the significance of TRA-1-60 on aggressive gastric adenocarcinoma showing therapeutic impact of CureMeta’s antibody-drug-conjugate CM-09 in a metastatic gastric cancer mouse model.
Patent on TRA-1-60 antibody
Filed patents on 11 antibodies specific to human cancers, including the lead therapeutic antibody Bstrongximab targeting TRA-1-60.